AARON KANTOFF, Director at Tourmaline Bio (NASDAQ:TRML), reported a large acquisition of company stock options on October 24, according to a new SEC filing.

What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that KANTOFF, Director at Tourmaline Bio, a company in the Health Care sector, was just awarded stock options worth 47,890 shares of TRML. The options give KANTOFF the right to buy the company's stock at $2.08 per share.

Tourmaline Bio shares are trading up 0.95% at $9.55 at the time of this writing on Tuesday morning. Since the current price is $9.55, this makes KANTOFF's 47,890 shares worth $478,900.

Now trade stocks online ...

Full story available on Benzinga.com